Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.

Summary

To determine whether a single dose of intravenous lornoxicam is superior to intravenous placebo for the acute treatment of moderate or severe headache associated with a single migraine attack in patients with a history of migraine. Two-thirds of patients in this study will receive a single dose of intravenous lornoxicam (8mg or 16 mg) and one-third of patients will receive a single dose of an intravenous placebo.

Timeline

Start

2005-12

Primary completion

2006-04

Completion

2006-04

Drugs

Indications